首页> 美国卫生研究院文献>Thoracic Cancer >Lactate dehydrogenase and baseline markers associated with clinical outcomes of advanced esophageal squamous cell carcinoma patients treated with camrelizumab (SHR‐1210) a novel anti‐PD‐1 antibody

【2h】

Lactate dehydrogenase and baseline markers associated with clinical outcomes of advanced esophageal squamous cell carcinoma patients treated with camrelizumab (SHR‐1210) a novel anti‐PD‐1 antibody

机译：乳酸抗脱氢酶和基线标志物与接受新型抗PD-1抗体卡雷珠单抗（SHR-1210）治疗的晚期食道鳞状细胞癌患者的临床结局相关

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

摘要
著录项
相似文献
相关主题

摘要

BackgroundA small proportion of patients with advanced esophageal squamous cell carcinoma (ESCC) could benefit from immune checkpoint inhibitors; however, reliable peripheral blood biomarkers for outcomes of anti‐PD‐1 immunotherapy in ESCC have not been identified.

机译：背景一小部分晚期食管鳞状细胞癌（ESCC）患者可受益于免疫检查点抑制剂。然而，尚未发现可用于ESCC抗PD-1免疫治疗结果的可靠外周血生物标志物。

著录项

期刊名称 Thoracic Cancer
作者
Xi Wang; Bo Zhang; Xuelian Chen; Hongnan Mo; Dawei Wu; Bo Lan; Qun Li; Binghe Xu; Jing Huang;
展开▼
作者单位

展开▼
年(卷),期 2019(10),6
年度 2019
页码 1395–1401
总页数 7
原文格式 PDF
正文语种
中图分类肿瘤学;
关键词
Esophageal squamous cell carcinoma immune checkpoint inhibitor lactate dehydrogenase markers programmed cell death‐1;

机译：食道鳞状细胞癌;免疫检查点抑制剂;乳酸脱氢酶;标志物;程序性细胞死亡-1;

相似文献

外文文献
中文文献
专利

1. Combination of Radiation Therapy and Anti-PD-1 Antibody SHR-1210 in Treating Patients with Esophageal Squamous Cell Cancer [J] . Jing Z., Du D., Zhang N., International Journal of Radiation Oncology, Biology, Physics . 2018,第3Suppla期

机译：放射治疗与抗PD-1抗体SHR-1210治疗食管鳞癌患者的组合
2. Safety and efficacy of programmed cell death‐1 antibody SHR‐1210 combined with concurrent chemoradiotherapy to treat locally advanced esophageal squamous cell carcinoma: a study protocol for an exploratory single‐arm phase Ib trial [J] . Xiaoying Wei, Zhoubo Guo, Wencheng Zhang, Precision Radiation Oncology . 2020,第4期

机译：编程细胞死亡-1抗体SHR-1210的安全性和有效性联合同时进行化学疗法，治疗局部晚期食管鳞状细胞癌：探索式单臂相位IB试验的研究方案
3. Safety, Activity, and Biomarkers of SHR-1210, an Anti-PD-1 Antibody, for Patients with Advanced Esophageal Carcinoma [J] . Jing Huang, Binghe Xu, Hongnan Mo, Clinical cancer research: an official journal of the American Association for Cancer Research . 2018,第6期

机译：SHR-1210的安全性，活性和生物标志物，抗PD-1抗体，用于晚期食管癌患者
4. IL-12 is a Useful Marker to Predict Clinical Outcome in Radiotherapy: Down-Regulation of IL-12 Increases Treatment Failure in Locally Advanced Hepatocellular Carcinoma [C] . En-Jung Lee, Yan-Gun Suh, Seojin Lee, International Molecular Medicine Tri-Conference. . 2015

机译：IL-12是一种有用的标记，可预测放疗中的临床结果：IL-12的下调增加了局部晚期肝细胞癌的治疗失败
5. Identifying Pathologic and Molecular Features that Predict Adverse Clinical Outcomes in Vulvar Squamous Cell Carcinoma. [D] . Holthoff, Emily Ruth. 2016

机译：鉴定可预测外阴鳞状细胞癌不良临床结果的病理和分子特征。
6. SHR‐1316 an anti‐PD‐L1 antibody plus chemotherapy as the first‐line treatment for advanced esophageal squamous cell carcinoma: A multicentre phase 2 study [O] . Lan Mu, Yan Song, Kuaile Zhao, 2021

机译：SHR-1316抗PD-L1抗体加上化疗作为先进食道鳞状细胞癌的第一线治疗：多期第2期研究
7. Safety and Efficacy of PD-1 Antibody SHR-1210 Combined with Concurrent Chemoradiotherapy to Treat Locally Advanced Esophageal Squamous Cell Carcinoma: A Phase Ib Clinical Trial [O] . Q. Pang, W. Zhang, J. Zhao, 2020

机译：PD-1抗体SHR-1210的安全性和功效联合同时的化疗治疗局部晚期食管鳞状细胞癌：IA相临床试验

Lactate dehydrogenase and baseline markers associated with clinical outcomes of advanced esophageal squamous cell carcinoma patients treated with camrelizumab (SHR‐1210) a novel anti‐PD‐1 antibody

摘要

著录项

相似文献

相关主题

期刊订阅